NVIDIA has secured partnerships with Eli Lilly, Thermo Fisher Scientific, and Tetrascience to establish BioNeMo as the dominant AI infrastructure for drug discovery.1 The coordinated moves create a vertically integrated ecosystem spanning pharmaceutical development, lab equipment, and data integration.
BioNeMo provides pre-trained AI models for molecular structure prediction, protein design, and drug-target interaction analysis.1 Lilly will use the platform to accelerate early-stage drug discovery, while Thermo Fisher integrates BioNeMo into laboratory equipment workflows.1
Tetrascience's data platform now channels experimental results directly into BioNeMo models, eliminating the need for separate data preprocessing infrastructure.1 This integration forces biotech companies using Tetrascience's systems to adopt NVIDIA's AI stack or build costly alternatives.
Six AI-native biotech firms have launched foundation models on or alongside BioNeMo infrastructure: Terray Therapeutics, Apheris, Basecamp Research, Owkin, Boltz Lab, and Edison Scientific.1 Each company contributes specialized models while relying on BioNeMo's base architecture, reinforcing the platform's network effects.
The partnerships mirror NVIDIA's playbook in autonomous vehicles and robotics—provide free or subsidized infrastructure, then capture recurring revenue through compute sales and licensing as adoption scales. Pharmaceutical companies face a choice: build proprietary AI stacks at high cost or accept vendor lock-in through BioNeMo.
Thermo Fisher's integration is particularly strategic. The company supplies lab equipment to most major pharmaceutical and biotech firms. Embedding BioNeMo into these instruments makes NVIDIA's AI the default option for millions of experiments annually.
The timing exploits pharmaceutical urgency around AI adoption. Traditional drug discovery takes 10-15 years and costs over $2 billion per approved drug. AI promises to cut both timelines and costs, creating pressure to adopt platforms with the largest training datasets and model libraries—advantages BioNeMo is rapidly accumulating through these partnerships.